概述
-
货号
FHC21030
-
种属反应性
Human -
宿主
Human -
同种型
IgG1, kappa -
克隆类型
Monoclonal -
偶联物
Unconjugated -
靶标
Meconium antigen 100, CEACAM5, CEA, CD66e, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen -
浓度
1 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P06731 -
克隆号
RG7813
-
应用
FCM -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
图片
参考文献
- CEA TCB, a novel T-cell bispecific antibody with potent in vitro and in vivo antitumor activity against solid tumors
- Cytokines in the Treatment of Melanoma
- Combining CEA-IL2v and FAP-IL2v immunocytokines with PD-L1 checkpoint blockade
- CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.
- 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 …
- IL-2 based cancer immunotherapies: an evolving paradigm
- A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of …
- Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview
- ITOC2–037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours
- Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
- The application of Interleukin-2 family cytokines in tumor immunotherapy research
- Interleukin-2–based therapies in cancer
- Engineering cytokines for cancer immunotherapy: a systematic review
- Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy
- Engineered bifunctional proteins for targeted cancer therapy: prospects and challenges
- Influence of the tumor microenvironment on NK cell function in solid tumors
- Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob–Knob and Hole–Hole side products
- Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives
- Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity
- Enabling routine MHC-II-associated peptide proteomics for risk assessment of drug-induced immunogenicity
- Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion
- Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
评价
